Vertex Pharmaceuticals VRTX +1.22% Get Free Report has outperformed the market over the past 20 years by 10.58% on an ...

Vertex Pharmaceuticals just pulled out the big guns with a new $4 billion stock repurchase plan, cleverly named the "2025 ...

Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at any time, the Boston-based ...

Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of April 24, 2025, the average one-year price target for Vertex Pharmaceuticals is $513.38/share. The forecasts range from a low of $333.30 to a high of $647.85.

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of intellectual property rights ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522.

Vertex Pharmaceuticals (VRTX) shares fall after the company reported adjusted earnings per share for the first quarter that missed expectations. Analysts are mixed about the launch of the non ...

Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) first-quarter financial report. Vertex's first-quarter financial results didn't keep up with what investors have gotten used to ...